CompletedNot Applicable

Identification of New Markers in the Hypereosinophilic Syndrome

France41 participantsStarted 2010-06-29

Plain-language summary

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * dated and signed informed consent * virale serology negative or negative result less than 6 months * virale serology negative for HBV or vaccinated patient * insured * virale serology negative or negative result less than 6 months * negative pregnancy test or female menopause for at least 1 year Exclusion Criteria: * subject enable adult, under guardianship or under protective measures of justice * Refusal or inability to give informed consent * The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

What they're measuring

The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.

Timeframe: one month after patient inclusion

Trial details

NCT IDNCT01713504

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-07

View on ClinicalTrials.gov More Hypereosinophilic Syndrome trials